□據新華社電
國務院總理李(li)克強6月20日主持召開國務院常務會議,部(bu)署進一步緩解小微企業融(rong)資(zi)難(nan)融(rong)資(zi)貴,持續推動實(shi)(shi)體經濟(ji)降成本;確定加(jia)快已在境(jing)外上(shang)市(shi)新藥(yao)審批(pi)、落(luo)實(shi)(shi)抗癌藥(yao)降價措施(shi)、強化短缺藥(yao)供應保障;通過《醫療糾紛預防和處理條例(li)(草案)》。
會(hui)議(yi)(yi)指出,要堅持(chi)(chi)穩健中性的(de)貨(huo)幣(bi)政策(ce)(ce),保(bao)持(chi)(chi)流動性合(he)理充裕和金(jin)(jin)融(rong)(rong)穩定(ding)(ding)運(yun)行(xing)(xing),加(jia)強(qiang)政策(ce)(ce)統(tong)籌協調,鞏固經(jing)濟穩中向好態勢,增(zeng)(zeng)強(qiang)市場信(xin)(xin)心,促進比(bi)較充分就(jiu)業(ye),保(bao)持(chi)(chi)經(jing)濟運(yun)行(xing)(xing)在合(he)理區間。會(hui)議(yi)(yi)確定(ding)(ding)了進一步(bu)緩解(jie)小(xiao)(xiao)(xiao)(xiao)微(wei)(wei)(wei)企(qi)(qi)(qi)業(ye)融(rong)(rong)資(zi)(zi)難融(rong)(rong)資(zi)(zi)貴的(de)措(cuo)施:一是(shi)(shi)增(zeng)(zeng)加(jia)支(zhi)持(chi)(chi)小(xiao)(xiao)(xiao)(xiao)微(wei)(wei)(wei)企(qi)(qi)(qi)業(ye)和“三農”再(zai)貸(dai)(dai)(dai)(dai)(dai)款、再(zai)貼現額度(du),下調支(zhi)小(xiao)(xiao)(xiao)(xiao)再(zai)貸(dai)(dai)(dai)(dai)(dai)款利(li)率。完善考核機制(zhi),實現單戶授(shou)信(xin)(xin)總(zong)額1000萬(wan)元(yuan)(yuan)及(ji)以下小(xiao)(xiao)(xiao)(xiao)微(wei)(wei)(wei)企(qi)(qi)(qi)業(ye)貸(dai)(dai)(dai)(dai)(dai)款同比(bi)增(zeng)(zeng)速高于各項貸(dai)(dai)(dai)(dai)(dai)款增(zeng)(zeng)速,有貸(dai)(dai)(dai)(dai)(dai)款余額戶數高于上年同期(qi)水平。二是(shi)(shi)從今年9月(yue)1日至2020年底,將符合(he)條(tiao)件的(de)小(xiao)(xiao)(xiao)(xiao)微(wei)(wei)(wei)企(qi)(qi)(qi)業(ye)和個體工商戶貸(dai)(dai)(dai)(dai)(dai)款利(li)息收入免征增(zeng)(zeng)值稅單戶授(shou)信(xin)(xin)額度(du)上限(xian),由100萬(wan)元(yuan)(yuan)提高到(dao)500萬(wan)元(yuan)(yuan)。國家(jia)融(rong)(rong)資(zi)(zi)擔保(bao)基金(jin)(jin)支(zhi)持(chi)(chi)小(xiao)(xiao)(xiao)(xiao)微(wei)(wei)(wei)企(qi)(qi)(qi)業(ye)融(rong)(rong)資(zi)(zi)的(de)擔保(bao)金(jin)(jin)額占比(bi)不(bu)低于80%,其中支(zhi)持(chi)(chi)單戶授(shou)信(xin)(xin)500萬(wan)元(yuan)(yuan)及(ji)以下小(xiao)(xiao)(xiao)(xiao)微(wei)(wei)(wei)企(qi)(qi)(qi)業(ye)貸(dai)(dai)(dai)(dai)(dai)款及(ji)個體工商戶、小(xiao)(xiao)(xiao)(xiao)微(wei)(wei)(wei)企(qi)(qi)(qi)業(ye)主經(jing)營性貸(dai)(dai)(dai)(dai)(dai)款的(de)擔保(bao)金(jin)(jin)額占比(bi)不(bu)低于50%。三是(shi)(shi)禁(jin)止金(jin)(jin)融(rong)(rong)機構向小(xiao)(xiao)(xiao)(xiao)微(wei)(wei)(wei)企(qi)(qi)(qi)業(ye)貸(dai)(dai)(dai)(dai)(dai)款收取承諾費(fei)(fei)、資(zi)(zi)金(jin)(jin)管理費(fei)(fei),減少融(rong)(rong)資(zi)(zi)附加(jia)費(fei)(fei)用(yong)。四是(shi)(shi)支(zhi)持(chi)(chi)銀(yin)行(xing)(xing)開拓小(xiao)(xiao)(xiao)(xiao)微(wei)(wei)(wei)企(qi)(qi)(qi)業(ye)市場,運(yun)用(yong)定(ding)(ding)向降準等貨(huo)幣(bi)政策(ce)(ce)工具,增(zeng)(zeng)強(qiang)小(xiao)(xiao)(xiao)(xiao)微(wei)(wei)(wei)信(xin)(xin)貸(dai)(dai)(dai)(dai)(dai)供給(gei)能(neng)力,加(jia)快(kuai)已簽(qian)約(yue)債轉股項目落地。鼓勵未設立普(pu)惠金(jin)(jin)融(rong)(rong)事業(ye)部的(de)銀(yin)行(xing)(xing)增(zeng)(zeng)設社區、小(xiao)(xiao)(xiao)(xiao)微(wei)(wei)(wei)支(zhi)行(xing)(xing)。五是(shi)(shi)將單戶授(shou)信(xin)(xin)500萬(wan)元(yuan)(yuan)及(ji)以下的(de)小(xiao)(xiao)(xiao)(xiao)微(wei)(wei)(wei)企(qi)(qi)(qi)業(ye)貸(dai)(dai)(dai)(dai)(dai)款納(na)入中期(qi)借貸(dai)(dai)(dai)(dai)(dai)便利(li)合(he)格抵押品范圍。
為(wei)讓群眾早用(yong)上(shang)(shang)、用(yong)得起好(hao)藥(yao)(yao)(yao)(yao),解決(jue)好(hao)重(zhong)點民(min)生(sheng)問題,會議(yi)確(que)定,一是有序加(jia)快境外已上(shang)(shang)市(shi)(shi)新藥(yao)(yao)(yao)(yao)在境內上(shang)(shang)市(shi)(shi)審(shen)批。對(dui)治療罕(han)見(jian)病的(de)藥(yao)(yao)(yao)(yao)品(pin)和防(fang)治嚴(yan)重(zhong)危(wei)及(ji)生(sheng)命疾病的(de)部分(fen)藥(yao)(yao)(yao)(yao)品(pin)簡化上(shang)(shang)市(shi)(shi)要求(qiu),可(ke)提交境外取得的(de)全部研究資料等直(zhi)接申報上(shang)(shang)市(shi)(shi),監(jian)管部門(men)分(fen)別在3個(ge)月、6個(ge)月內審(shen)結。將進口化學藥(yao)(yao)(yao)(yao)品(pin)上(shang)(shang)市(shi)(shi)前注冊檢驗改為(wei)上(shang)(shang)市(shi)(shi)后監(jian)督抽樣,不作為(wei)進口驗放條件。二(er)是督促推動抗癌(ai)藥(yao)(yao)(yao)(yao)加(jia)快降價,讓群眾有更多獲得感(gan)。各省(sheng)(區(qu)、市(shi)(shi))對(dui)醫(yi)保目(mu)錄(lu)內的(de)抗癌(ai)藥(yao)(yao)(yao)(yao)要開展(zhan)專項(xiang)招標采購(gou)。對(dui)醫(yi)保目(mu)錄(lu)外的(de)獨家(jia)抗癌(ai)藥(yao)(yao)(yao)(yao)要抓緊推進醫(yi)保準入談(tan)判(pan)。開展(zhan)國(guo)家(jia)藥(yao)(yao)(yao)(yao)品(pin)集(ji)中采購(gou)試點,實現藥(yao)(yao)(yao)(yao)價明顯(xian)降低。三(san)是加(jia)強全國(guo)短(duan)缺(que)藥(yao)(yao)(yao)(yao)品(pin)供應(ying)保障監(jian)測預(yu)警,建立短(duan)缺(que)藥(yao)(yao)(yao)(yao)品(pin)及(ji)原料藥(yao)(yao)(yao)(yao)停產備(bei)(bei)案制度,加(jia)大儲備(bei)(bei)力度,確(que)保患者(zhe)用(yong)藥(yao)(yao)(yao)(yao)不斷供。
中(zhong)證(zheng)(zheng)(zheng)(zheng)網(wang)聲(sheng)明(ming)(ming):凡本(ben)網(wang)注(zhu)明(ming)(ming)“來源:中(zhong)國證(zheng)(zheng)(zheng)(zheng)券(quan)報(bao)·中(zhong)證(zheng)(zheng)(zheng)(zheng)網(wang)”的所有作(zuo)品(pin),版權(quan)均(jun)屬于中(zhong)國證(zheng)(zheng)(zheng)(zheng)券(quan)報(bao)、中(zhong)證(zheng)(zheng)(zheng)(zheng)網(wang)。中(zhong)國證(zheng)(zheng)(zheng)(zheng)券(quan)報(bao)·中(zhong)證(zheng)(zheng)(zheng)(zheng)網(wang)與作(zuo)品(pin)作(zuo)者(zhe)(zhe)聯(lian)合聲(sheng)明(ming)(ming),任(ren)何(he)組織(zhi)未經中(zhong)國證(zheng)(zheng)(zheng)(zheng)券(quan)報(bao)、中(zhong)證(zheng)(zheng)(zheng)(zheng)網(wang)以及作(zuo)者(zhe)(zhe)書面授權(quan)不(bu)(bu)得轉載、摘編或(huo)利用(yong)其(qi)(qi)它(ta)方式使用(yong)上(shang)述作(zuo)品(pin)。凡本(ben)網(wang)注(zhu)明(ming)(ming)來源非中(zhong)國證(zheng)(zheng)(zheng)(zheng)券(quan)報(bao)·中(zhong)證(zheng)(zheng)(zheng)(zheng)網(wang)的作(zuo)品(pin),均(jun)轉載自其(qi)(qi)它(ta)媒體,轉載目的在(zai)于更好服務讀(du)者(zhe)(zhe)、傳(chuan)遞信息之需,并不(bu)(bu)代(dai)表本(ben)網(wang)贊同其(qi)(qi)觀點(dian),本(ben)網(wang)亦不(bu)(bu)對其(qi)(qi)真(zhen)實性負責(ze),持(chi)異議者(zhe)(zhe)應與原出(chu)處單位主張(zhang)權(quan)利。
特別鏈接:政府部門交易機構證券期貨四所兩司新聞發布平臺友情鏈接版權聲明
關于報社關于本站廣告發布免責條款
中國證券報社版權所有,未經書面授權不得復制或建立鏡像 經營許可證編號:京B2-20180749 京公網安備0-1
Copyright 2001-2018 China Securities Journal. All Rights Reserved
中(zhong)國證券報社版權(quan)所(suo)有,未經(jing)書面授(shou)權(quan)不(bu)得復制或(huo)建立鏡(jing)像
經營(ying)許(xu)可證編號(hao):京(jing)B2-20180749 京(jing)公網安備0-1
Copyright 2001-2018 China Securities Journal. All Rights Reserved